Aug 12, 2026 04:05PM
Jul 29, 2026 08:32AM
Jul 29, 2026 08:30AM
Jul 15, 2026 08:30AM
Jul 15, 2026 08:30AM
Apr 15, 2026 08:31AM
Apr 15, 2026 08:30AM Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Apr 13, 2026 11:13AM
Jan 12, 2026 10:14AM
Dec 15, 2025 05:40PM
Dec 15, 2025 05:39PM
Nov 6, 2025 04:05PM
Nov 3, 2025 09:04AM
Aug 13, 2025 04:05PM Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Aug 1, 2025 08:31AM
Aug 1, 2025 08:30AM
Jun 1, 2025 10:45AM
May 22, 2025 05:21PM
May 22, 2025 05:17PM
Apr 23, 2025 10:12AM
Apr 7, 2025 08:31AM Allogene Therapeutics (ALLO) Granted Three FDA Fast Track Designations for ALLO-329,
Apr 7, 2025 08:30AM
Mar 13, 2025 04:02PM
Feb 25, 2025 04:11PM
Feb 25, 2025 04:10PM
Feb 13, 2025 04:30PM
Feb 13, 2025 04:30PM
Jan 28, 2025 08:31AM Allogene Therapeutics (ALLO) Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Jan 28, 2025 08:30AM
Jan 2, 2025 04:00PM
Nov 18, 2024 08:37AM
Nov 18, 2024 08:30AM
Nov 7, 2024 04:02PM
Nov 7, 2024 10:00AM
Nov 7, 2024 10:00AM Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Nov 5, 2024 09:10AM
Oct 30, 2024 08:14AM
Oct 29, 2024 08:30AM
Oct 29, 2024 08:30AM
Sep 26, 2024 08:33AM
Sep 26, 2024 08:30AM
Aug 7, 2024 04:02PM Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
Jul 1, 2024 08:30AM
Jun 20, 2024 08:30AM
May 13, 2024 04:01PM
Apr 26, 2024 08:32AM
Apr 26, 2024 08:30AM
Apr 26, 2024 08:30AM
Mar 14, 2024 04:05PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Mar 12, 2024 08:30AM

329,915 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All